Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neisseria meningitidis group C (strain C11) polysaccharide (de-O-acetylated) conjugated to tetanus toxoid
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
neisseria meningitidis group C (strain C11) polysaccharide (de-O-acetylated) conjugated to tetanus toxoid is a monovalent conjugate vaccine developed by Sanofi Pasteur for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroup C. The vaccine utilizes a capsular polysaccharide derived from the C11 strain, which has been de-O-acetylated to potentially enhance the induction of high-avidity bactericidal antibodies. This polysaccharide is covalently linked to a tetanus toxoid carrier protein, which converts the T-cell independent polysaccharide antigen into a T-cell dependent antigen, thereby inducing immunological memory and a more robust immune response, particularly in infants and young children. It is typically administered via intramuscular injection and is used in various national immunization programs, including in Brazil, and is WHO prequalified.
- Brand names
- Meningococcal Group C Conjugate Vaccine
- Other names
- Meningococcal serogroup C conjugate vaccineMenC-TT vaccineDe-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate
02
Targets
Neisseria meningitidis group C capsular polysaccharideTT (Tetanus toxoid)
Beyond the preview
Go deeper on neisseria meningitidis group C (strain C11) polysaccharide (de-O-acetylated) conjugated to tetanus toxoid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neisseria meningitidis group C (strain C11) polysaccharide (de-O-acetylated) conjugated to tetanus toxoid.